Minimally Invasive Device Therapy for BPH
Location: United States, Wisconsin, Milwaukee
Employees: 1-10
Total raised: $32.1M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.10.2024 | Series C | $30M | - |
| 27.07.2023 | - | $2.1M | - |
Mentions in press and media 6
| Date | Title | Description |
| 17.10.2024 | Rivermark Medical Secures $30 Million to Revolutionize BPH Treatment | Rivermark Medical is on the brink of a breakthrough. The Milwaukee-based company has successfully raised $30 million in a Series C funding round. This financial boost is set to propel the development of its flagship product, the FloStent Sy... |
| 15.10.2024 | Rivermark Medical: $30 Million (Series C) Closed To Advance Development Of Flostent | Rivermark Medical, a leader in minimally invasive solutions for Benign Prostatic Hyperplasia (BPH), announced the closing of a $30 million Series C financing round. The funding round was led by American Century Investments (ACI), including ... |
| 10.10.2024 | Rivermark Medical Raises $30M in Series C Funding | Rivermark Medical, a Milwaukee, WI-based company which specializes in minimally invasive solutions for Benign Prostatic Hyperplasia (BPH), raised $30M in Series C funding. The round was led by American Century Investments (ACI) including ne... |
| 28.08.2023 | Wisconsin VC Funding for July 2023 | According to Pitchbook, Wisconsin startups raised at least $10.65 million in July. Milwaukee-based Rivermark Medical has developed a therapeutic device that provides a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH). Le... |
| - | Rivermark Medical | “Rivermark” |
| - | Rivermark Medical raises $30M to advance commercialization of first product | - |